HigherHighs
RankingLoading... stocks
USA
NASDAQ
Healthcare
Biotechnology
NGNE (USA) - Neurogene Inc
1W
1M
3M
6M
1Y
2Y
5Y
All
ABOUT Neurogene Inc
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.